Riskpilot← Back to searchSign inGet full accessHEALTHTECH SCIENCES AS
ASActiveOrg 892976562Rieber-Mohns Veg 2, 5230 ParadisWholesale of pharmaceutical and medical goods · NACE 4646Est. 20086 employees
Revenue 2024
NOK 6,6M
+20% vs 2023
EBITDA margin
13.8%
+292% vs 2023
Equity ratio
39.5%
Financial strength
Net profit 2024
NOK 882K
+235% vs 2023
| Revenue | NOK 6,6M | +20% |
| EBITDA | NOK 916K | +292% |
| Net profit | NOK 882K | +235% |
| Total assets | NOK 1,9M | +20% |
| Equity | NOK 740K | +630% |
| Employees | 6 | — |
Legal name
HEALTHTECH SCIENCES AS
Org number
892976562
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. august 2008
Share capital
NOK 220 422
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder hver for seg.
Company purpose
Salg av medisinsk utstyr og andre helseprodukter. Samt det som naturlig faller inn under dette.
Address
Rieber-Mohns Veg 2, 5230 Paradis
Phone
+4755629595
Email
bergen@healthoptimizing.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 527 | 2 881 | 3 152 | 3 138 | 2 708 | 2 146 | 4 732 | 4 957 | 4 444 | 10 720 | 11 604 | 8 593 | 6 359 | 5 213 | 4 751 | 5 540 | 6 639 |
| Staff expenses | −1 213 | −703 | −860 | −736 | −1 060 | −1 732 | −1 954 | −2 887 | −3 041 | −4 019 | −4 991 | −4 728 | −2 013 | −1 666 | −1 359 | −2 532 | −2 347 |
| EBITDA | 917 | −628 | 125 | 206 | −658 | −2 326 | −319 | −3 523 | −957 | 396 | 338 | −1 318 | −844 | −317 | 359 | −476 | 916 |
| Depreciation & amort. | −155 | −165 | −141 | −104 | −49 | −29 | −29 | −8 | −23 | −44 | −72 | −72 | −164 | −144 | −129 | −64 | −80 |
| EBIT | 761 | −793 | −17 | 102 | −708 | −2 355 | −348 | −3 531 | −979 | 353 | 267 | −1 390 | −1 008 | −460 | 230 | −540 | 836 |
| Net financials | −540 | −3 | 40 | −140 | −16 | 151 | 21 | −33 | −79 | −208 | 43 | 9 | 21 | −43 | 44 | −113 | 46 |
| Profit before tax | 222 | −796 | 23 | −38 | −724 | −2 204 | −327 | −3 564 | −1 058 | 145 | 310 | −1 381 | −987 | −503 | 274 | −653 | 882 |
| Tax | 86 | −108 | −125 | 274 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 136 | −687 | 147 | −312 | −724 | −2 204 | −327 | −3 564 | −1 058 | 145 | 310 | −1 381 | −987 | −503 | 274 | −653 | 882 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 822 | 2 277 | 3 055 | 2 577 | 3 946 | 1 724 | 2 863 | 1 344 | 1 980 | 3 009 | 2 854 | 2 883 | 2 908 | 1 744 | 2 055 | 1 561 | 1 873 |
| Equity | 177 | 1 536 | 2 309 | 1 997 | 2 773 | 569 | 2 093 | −1 472 | 1 104 | 1 249 | 1 559 | 1 729 | 743 | 239 | 514 | −140 | 740 |
| Long-term debt | 2 054 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 517 | 1 011 | 895 | 890 | 611 |
| Short-term debt | 591 | 740 | 747 | 580 | 1 173 | 1 154 | 770 | 2 816 | 1 376 | 1 760 | 1 296 | 1 154 | 648 | 493 | 646 | 811 | 521 |
| Total debt | 2 644 | 740 | 747 | 580 | 1 173 | 1 154 | 770 | 2 816 | 1 376 | 1 760 | 1 296 | 1 154 | 2 165 | 1 504 | 1 541 | 1 701 | 1 133 |
EBITDA margin
13.8%
This company
15.8%
Market median
-13% vs market
20082024
Equity ratio
39.5%
This company
38.2%
Market median
+3% vs market
20082024
Return on equity
119.1%
This company
18.4%
Market median
+547% vs market
20082024
Net profit margin
13.3%
This company
8.1%
Market median
+64% vs market
20082024
Asset turnover
3.54×
This company
1.12×
Market median
+216% vs market
20082024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RH Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Chairman | 2018 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
New Health Paradigm As | Company | 50.0% | 50.0% | 2024 |
Enpro-Invest As | Company | 27.6% | 27.6% | 2024 |
| Individual | 6.5% | 6.5% | 2024 | |
Fifth Set Ventures | Company | 5.2% | 5.2% | 2024 |
Karlson Invest As | Company | 3.2% | 3.2% | 2024 |
Kts Consult As | Company | 3.2% | 3.2% | 2024 |
Henning Swiboda | Company | 2.5% | 2.5% | 2023 |
| Individual | 2.5% | 2.5% | 2024 | |
Jonathan Moyle | Company | 1.4% | 1.4% | 2024 |
| Individual | 1.4% | 1.4% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HEALTHTECH SCIENCES AS 
HELSEPAKKEN ASBoard members of HEALTHTECH SCIENCES AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Roger Hovland | Chief Executive Officer | 0 companies |
| Thomas Aksnes | Deputy Chairman | 0 companies |
| Kari Tvete Solvang | Chairman | 0 companies |
| Brit Solvang Karlson | Board of Directors | 0 companies |
| Haavard Helmen | Board of Directors | 0 companies |